Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study

The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily × 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment. There were no responses in 14 evaluable patients...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of neurological sciences 1990-02, Vol.17 (1), p.21-23
Main Authors: Cairncross, J. Gregory, Eisenhauer, Elizabeth A., Macdonald, David R., Rathbone, Michel P., Moore, Malcolm J., Sawka, Carol A., MacCormick, Ronald E., Kerr, Ian G.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Canada
Drug Evaluation
Female
Glioma - drug therapy
Humans
Injections, Intravenous
Male
Middle Aged
Original Articles
Quinazolines - administration & dosage
Quinazolines - therapeutic use
Trimetrexate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily × 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment. There were no responses in 14 evaluable patients. We conclude that trimetrexate, given as described, is not an active agent in this disease.
ISSN:0317-1671
2057-0155
DOI:10.1017/S0317167100029966